On this week's episode of the Business of Biotech podcast, Diamyd Medical’s president and CEO, Dr. Ulf Hannelius, talks about developing therapies aimed at preserving and restoring insulin production in Type 1 diabetes patients, plus the why and the how behind the company's choice to manufacture them in-house. Listen now and subscribe so you never miss an episode. Articles
NervGen Pharma is going beyond preclinicals to human trials for a drug that could repair and regrow neurons.
Women make up 65% of workers in the health sector and are responsible for approximately 80% of consumer buying and healthcare decisions in the United States. Yet they make up barely one-third of senior leadership positions within the industry and only 13% of CEOs.